Rallybio CFO Jonathan Lieber moves to part-time role, keeps title until Avenzo merger
Rallybio's Chief Financial Officer, Jonathan Lieber, will move to part-time employment effective September 15, 2026, but will remain CFO and Principal Financial Officer with the same duties and authority. His employment will end when the pending business combination with Avenzo Therapeutics closes, unless it is terminated earlier.
Key points
- Part-time transition effective September 15, 2026; he keeps the CFO and principal financial officer titles
- Base salary of $420,000 after the transition, with benefit plan participation
- No annual bonus for 2026 or any later year he is employed
- Employment ends at the closing of the Avenzo merger agreement dated May 31, 2026; severance follows under his existing employment agreements
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.